Semaglutide TabletsTablet
Weight Loss & GLP-1 Agonists

Semaglutide Tablets

Semaglutide

World's first oral GLP-1 receptor agonist (Rybelsus) utilizing SNAC absorption technology to enable gastrointestinal uptake of this large peptide molecule, providing once-daily tablet convenience for type 2 diabetes management with HbA1c reductions comparable to injectable GLP-1 agonists. Supplied in 30-tablet bottles from Novo Nordisk-aligned and Indian manufacturers and exported for diabetes management programs preferring non-injectable therapy.

Strengths

3mg / 7mg / 14mg

Packing

30 tablets/bottle

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Semaglutide 3mg / 7mg / 14mg with SNAC absorption enhancer
Dosage Form
Tablet
Available Strengths
3mg / 7mg / 14mg
Packing
30 tablets/bottle
Route of Administration
Oral, on empty stomach with ≤120ml water, 30 min before food
Dosage
3mg once daily for 30 days, then 7mg; may increase to 14mg after 30 days
Indications
Type 2 diabetes mellitus, cardiovascular risk reduction in T2DM with established CVD
Country of Origin
India (WHO-GMP Certified)
Storage
Store below 30°C, protect from moisture, keep in original blister
Shelf Life
36 months
Side Effects
Nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation
Precautions
Must take on empty stomach with minimal water; 30-min fasting after dose; thyroid C-cell tumor risk; pancreatitis risk; diabetic retinopathy complications possible

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Retatrutide InjectionInjection

Retatrutide Injection

Retatrutide

Investigational triple incretin receptor agonist (GIP/GLP-1/Glucagon) demonstrating exceptional weight loss exceeding 24% body weight in Phase 2 trials, surpassing all currently approved anti-obesity medications and representing the next generation of metabolic therapies. Supplied by Indian manufacturers for research procurement and supplied to markets where investigational compounds are accessible under physician oversight.

5mg / 10mg / 20mg
Tirzepatide InjectionInjection

Tirzepatide Injection

Tirzepatide

First-in-class dual GIP/GLP-1 receptor agonist (twincretin) demonstrating superior HbA1c reduction and up to 22.5% body weight loss in SURPASS and SURMOUNT trials, outperforming semaglutide across all dose levels in head-to-head studies. Available in six escalating weekly dose strengths as a single-dose auto-injector pen, supplied by Eli Lilly-aligned and Indian generic manufacturers for diabetes and obesity management globally.

2.5mg / 5mg / 7.5mg / 10mg / 12.5mg / 15mg
Semaglutide InjectionInjection

Semaglutide Injection

Semaglutide

Long-acting GLP-1 receptor agonist with a 168-hour half-life enabling once-weekly subcutaneous dosing for type 2 diabetes (Ozempic, up to 2mg) and chronic weight management (Wegovy, 2.4mg), with proven cardiovascular risk reduction in the SUSTAIN and STEP trial programs. Available as a pre-filled pen from Novo Nordisk-aligned and Indian generic manufacturers and exported globally as one of the most prescribed GLP-1 agents for diabetes and obesity.

0.25mg / 0.5mg / 1mg / 2.4mg

Need bulk pricing for Semaglutide Tablets?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote